Atossa Therapeutics Q3 EPS $(0.05) Beats $(0.07) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics (NASDAQ:ATOS) reported a Q3 EPS loss of $(0.05), surpassing the consensus estimate of $(0.07) by 28.57%. This represents a 16.67% improvement from the $(0.06) per share loss reported in the same quarter of the previous year.
November 14, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics reported better-than-expected Q3 EPS, showing an improvement from the previous year and beating analyst estimates.
Beating EPS estimates typically generates positive investor sentiment, which can lead to a short-term increase in stock price. The improvement from the previous year's loss may also be viewed favorably by the market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100